FPFS 1169

Drug Profile

FPFS 1169

Alternative Names: -(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride; 1-(benzofuran-2-yl)-2-propylaminopentane; Benzofuranylpropylaminopentane; BPAP-cpd; FPFS1169; R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane; R-(-)-BPAP; R-FPFS-1169

Latest Information Update: 23 Jul 2014

Price : $50

At a glance

  • Originator Fujimoto Pharmaceutical
  • Class Antiparkinsonians; Benzofurans; Neuroprotectants; Propylamines; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Catecholamine receptor agonists; Proto-oncogene proteins c-bcl-2 stimulants; Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 23 Jul 2014 No development reported - Phase-II for Parkinson's disease in United Kingdom (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top